J&J nabs new OK for IL-23 drug Trem­fya; Mer­ck KGaA spin­out ups Se­ries A tal­ly to €20.1M

→ J&J has got­ten the green­light to add ac­tive pso­ri­at­ic arthri­tis to Trem­fya’s la­bel. The drug “is the first and on­ly se­lec­tive IL-23 in­hibitor ap­proved for both ac­tive pso­ri­at­ic arthri­tis and mod­er­ate to se­vere plaque pso­ri­a­sis, as well as the on­ly bi­o­log­ic ap­proved for the treat­ment of pso­ri­at­ic arthri­tis to have im­prove­ment in fa­tigue as mea­sured by FAC­IT-F in­clud­ed in the U.S. Pre­scrib­ing In­for­ma­tion,” David Lee, the ther­a­peu­tic head of im­munol­o­gy at Janssen, said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER